REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.
Details of the planned presentations are listed below:
Revolution Medicines Oral Presentations:
Title:
Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor
Presenter:
Jim Cregg, Ph.D.
Abstract Number:
ND07
Session:
New Drugs on the Horizon: Part 2
Date/Time:
3:45 – 4:00 p.m. Eastern on April 16, 2023
Title:
RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models
Presenter:
Marie Menard, Ph.D.
Abstract Number:
3475
Session:
Immune Checkpoints at Tumor Beds
Date/Time:
3:37 – 3:52 p.m. Eastern on April 17, 2023
Revolution Medicines Poster Presentations:
Title:
RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Presenter:
Lingyan Jiang, Ph.D.
Abstract Number:
526/26
Session:
Novel Antitumor Agents 2
Date/Time:
1:30 – 5:00 p.m. Eastern on April 16, 2023
Title:
RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target
Presenter:
Yu C. Yang, Ph.D.
Abstract Number:
1598/21
Session:
New Therapeutic Targeted Agents
Date/Time:
9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023
Collaborator Oral Presentation:
Title:
Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer
Abstract Number:
5733
Session:
New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling
Presentation Time:
2:37 – 2:52 p.m. Eastern on April 18, 2023
Collaborator Poster Presentations:
Title:
Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression
Abstract Number:
LB015/7
Session:
Late-Breaking Research: Experimental and Molecular Therapeutics 1
Presentation Time:
1:30 – 5:00 p.m. Eastern on April 16, 2023
Title:
Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma
Abstract Number:
1725/22
Session:
Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2
Date/Time:
9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023
Title:
Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1
Abstract Number:
4859/2
Session:
Anticancer Approaches Targeting Signal Transduction Pathways
Presentation Time:
1:30 – 5:00 p.m. Eastern on April 18, 2023
Additional information on the AACR Annual Meeting 2023 is available through the AACR website at:
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D) and RMC-0708 (KRASQ61H), both of which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
Contacts:
For Investors & Media:
Erin Graves
650-779-0136
egraves@revmed.com
